www.medicinapropraxi.cz 312 MEDICÍNA PRO PRAXI / Med. Praxi. 2024;21(5):306-313 / SDĚLENÍ Z PRAXE Kritické zhodnocení intravenózně podávaného vitaminu C v praxi Závěrem lze říci, že se postupně shromažďuje velké množství důkazů o VitC, a sice, pokud je podáván intravenózně a ve vysokých dávkách, má silné cytotoxické vlastnosti selektivní vůči rakovině. Je však na druhou stranu nutno vzpomenout, že dosavadní kvalita a množství informací jsou relativně nízké a potřebují značné rozšíření, proto je určitá míra obezřetnosti a skepticismu na místě. Celkový pohled na dané přípravky navíc zkaluje fakt, že IVC nejsou v České republice hrazené ze zdravotního pojištění a aktuálně jsou nejčastěji podávány na soukromých klinikách za cenu řádově v jednotkách tisíc Kč. Vzhledem k tomu, že zavedení vysokodávkového IVC by mohlo být průlomem v léčbě onkologických pacientů se špatnou prognózou a málo dostupnými možnostmi léčby, je žádoucí apelovat na lékaře používající tyto přípravky k vyčerpávajícímu sdílení jejich zkušeností a zpětné vazby od pacientů. LITERATURA 1. Carpenter KJ. The history of scurvy and vitamin C (Transferred to digital printing). Cambridge Univ. Pr; 2003. 2. Padayatty SJ, Levine M. Vitamin C: the known and the unknown and Goldilocks. Oral, DiS. 2016 Sep;22(6):463-93. doi: 10.1111/odi.12446. Epub 2016 Apr 14. PMID: 26808119; PMCID: PMC4959991. 3. Rebouche CJ. Renal handling of carnitine in experimental vitamin C deficiency. Metabolism. 1995 Dec;44(12):1639-43. doi: 10.1016/0026-0495(95)90087-x. PMID: 8786736. 4. Ronchetti IP, Quaglino D Jr, Bergamini G. Ascorbic acid and connective tissue. Subcell Biochem. 1996;25:249-64. doi: 10.1007/978-1-4613-0325-1_13. PMID: 8821978. 5. Katsuki H. Vitamin C and nervous tissue. In vivo and in vitro aspects. Subcell Biochem. 1996;25:293-311. doi: 10.1007/9781-4613-0325-1_15. PMID: 8821980. 6. Horrobin DF. Ascorbic acid and prostaglandin synthesis. Subcell Biochem. 1996;25:109-15. doi: 10.1007/978-1-46130325-1_6. PMID: 8821971. 7. Heller R, Münscher‑Paulig F, Gräbner R, et al. L‑Ascorbic acid potentiates nitric oxide synthesis in endothelial cells. J Biol Chem. 1999 Mar 19;274(12):8254-60. doi: 10.1074/ jbc.274. 12. 8254. PMID: 10075731. 8. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD000980. doi: 10.1002/14651858.CD000980. pub4. PMID: 23440782; PMCID: PMC8078152. 9. Hemilä H, Chalker E. Vitamin C reduces the severity of common colds: a meta‑analysis. BMC Public Health. 2023 Dec 11;23(1):2468. doi: 10.1186/s12889-023-17229-8. PMID: 38082300; PMCID: PMC10712193. 10. Coulter ID, Hardy ML, Morton SC, et al. Antioxidants vitamin C and vitamin e for the prevention and treatment of cancer. J Gen Intern Med. 2006 Jul;21(7):735-44. doi: 10.1111/j.1525-1497.2006.00483.x. PMID: 16808775; PMCID: PMC1924689. 11. Gaziano JM, Glynn RJ, Christen WG, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians‘ Health Study II randomized controlled trial. JAMA. 2009 Jan 7;301(1):52-62. doi: 10.1001/jama.2008.862. Epub 2008 Dec 9. PMID: 19066368; PMCID: PMC2774210. 12. Wang L, Sesso HD, Glynn RJ, et al. Vitamin E and C supplementation and risk of cancer in men: posttrial follow‑up in the Physicians‘ Health Study II randomized trial. Am J Clin Nutr. 2014 Sep;100(3):915-23. doi: 10.3945/ajcn.114.085480. Epub 2014 Jul 9. PMID: 25008853; PMCID: PMC4135500. 13. Lin J, Cook NR, Albert C, et al. Vitamins C and E and beta carotene supplementation and cancer risk: a randomized controlled trial. J Natl Cancer Inst. 2009 Jan 7;101(1):14-23. doi: 10.1093/jnci/djn438. Epub 2008 Dec 30. PMID: 19116389; PMCID: PMC2615459. 14. Ma Y, Chapman J, Levine M, et al. High‑dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014 Feb 5;6(222):222ra18. doi: 10.1126/scitranslmed.3007154. PMID: 24500406. 15. Monti DA, Mitchell E, Bazzan AJ, et al. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. doi: 10.1371/journal. pone.0029794. Epub 2012 Jan 17. PMID: 22272248; PMCID: PMC3260161. 16. Ou J, Zhu X, Chen P, et al. A randomized phase II trial of best supportive care with or without hyperthermia and vitamin C for heavily pretreated, advanced, refractory non ‑small‑cell lung cancer. J Adv Res. 2020 Mar 17;24:175-182. doi: 10.1016/j.jare.2020. 03. 004. PMID: 32368355; PMCID: PMC7190757. 17. Welsh JL, Wagner BA, van’t Erve TJ, et al. Pharmacological ascorbate with gemcitabine for the control of metastatic and node‑positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5. PMID: 23381814; PMCID: PMC3587047. 18. Böttger F, Vallés‑Martí A, Cahn L, et al. High‑dose intravenous vitamin C, a promising multi‑targeting agent in the treatment of cancer. J Exp Clin Cancer Res. 2021 Oct 30;40(1):343. doi: 10.1186/s13046-021-02134-y. PMID: 34717701; PMCID: PMC8557029. 19. Doseděl M, Jirkovský E, Macáková K, et al. Vitamin C‑Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination. Nutrients. 2021 Feb 13;13(2):615. doi: 10.3390/ nu13020615. PMID: 33668681; PMCID: PMC7918462. 20. Isola S, Gammeri L, Furci F, et al. Vitamin C Supplementation in the Treatment of Autoimmune and Onco ‑Hematological Diseases: From Prophylaxis to Adjuvant Therapy. Int J Mol Sci. 2024 Jul 2;25(13):7284. doi: 10.3390/ ijms25137284. PMID: 39000393; PMCID: PMC11241675. 21. Klener P, Scott Alexander M, Cullen JJ, et al. The benefits of ascorbate to protect healthy cells in the prevention and treatment of oncological diseases. J Appl Biomed. 2020 Mar;18(1):1-7. doi: 10.32725/jab.2020.003. Epub 2020 Feb 19. PMID: 34907706. 22. Pereira M, Cardeiro M, Frankel L, et al. Increased Vitamin C Intake Is Associated With Decreased Pancreatic Cancer Risk. World J Oncol. 2024 Aug;15(4):543-549. doi: 10.14740/wjon1854. Epub 2024 Jul 5. PMID: 38993260; PMCID: PMC11236377. 23. Conte E, Rizzolo E, Flower G, et al. Intravenous Vitamin C in Cancer Care: Evidence Review and Practical Guidance for Integrative Oncology Practitioners. CAND Journal. 2024; 31(1):Article 1. https://doi.org/10.54434/candj.149. 24. Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high‑dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974 Oct;9(4):285-315. doi: 10.1016/0009-2797(74)90019-2. PMID: 4430016. 25. Moertel CG, Fleming TR, Creagan ET, et al. High‑dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double‑blind comparison. N Engl J Med. 1985 Jan 17;312(3):137-41. doi: 10.1056/NEJM198501173120301. PMID: 3880867. 26. Stephenson CM, Levin RD, Spector T, et al. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high‑dose intravenous ascorbic acid in patients with advanced cancer. Cancer Chemother Pharmacol. 2013 Jul;72(1):139-46. doi: 10.1007/s00280-013-2179-9. Epub 2013 May 14. PMID: 23670640; PMCID: PMC3691494. 27. Chen Q, Espey MG, Sun AY, et al. Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9. doi: 10.1073/pnas.0804226105. Epub 2008 Aug 4. PMID: 18678913; PMCID: PMC2516281. 28. Polireddy K, Dong R, Reed G, et al. High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study. Sci Rep. 2017 Dec 7;7(1):17188. doi: 10.1038/s41598-017-17568-8. PMID: 29215048; PMCID: PMC5719364. 29. Schoenfeld JD, Sibenaller ZA, Mapuskar KA, et al. O2- and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate. Cancer Cell. 2017 Apr 10;31(4):487-500.e8. doi: 10.1016/j.ccell.2017. 02. 018. Epub 2017 Mar 30. Erratum in: Cancer Cell. 2017 Aug 14;32(2):268. doi: 10.1016/j.ccell.2017. 07. 008. PMID: 28366679; PMCID: PMC5497844. 30. Takahashi H, Mizuno H, Yanagisawa A. High‑dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe. 2012;1:49-53. https://doi.org/10.1016/j.pmu.2012. 05. 008. 31. Vollbracht C, Schneider B, Leendert V, et al. Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. In Vivo. 2011 Nov‑Dec;25(6):983-90. PMID: 22021693. 32. Yeom CH, Jung GC, Song KJ. Changes of terminal cancer patients‘ health‑related quality of life after high dose vitamin C administration. J Korean Med Sci. 2007 Feb;22(1):711. doi: 10.3346/jkms.2007. 22. 1. 7. PMID: 17297243; PMCID: PMC2693571. 33. Riordan HD, Casciari JJ, González MJ, et al. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005 Dec;24(4):269-76. PMID: 16570523. 34. Nielsen TK, Højgaard M, Andersen JT, et al. Weekly ascorbic acid infusion in castration‑resistant prostate cancer patients: a single‑arm phase II trial. Transl Androl Urol. 2017 Jun;6(3):517-528. doi: 10.21037/tau.2017. 04. 42. PMID: 28725594; PMCID: PMC5503969. 35. Hoffer LJ, Levine M, Assouline S, et al. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008 Nov;19(11):1969-74. doi: 10.1093/annonc/mdn377. Epub 2008 Jun 9. Erratum in: Ann Oncol. 2008 Dec;19(12):2095. PMID: 18544557. 36. Ferraro PM, Curhan GC, Gambaro G, et al. Total, Dietary, and Supplemental Vitamin C Intake and Risk of Incident Kidney Stones. Am J Kidney, DiS. 2016 Mar;67(3):4007. doi: 10.1053/j.ajkd.2015. 09. 005. Epub 2015 Oct 14. PMID: 26463139; PMCID: PMC4769668. 37. Thomas LD, Elinder CG, Tiselius HG, et al. Ascorbic acid supplements and kidney stone incidence among men: a prospective study. JAMA Intern Med. 2013 Mar 11;173(5):3868. doi: 10.1001/jamainternmed.2013.2296. PMID: 23381591. 38. Drisko JA, Chapman J, Hunter VJ. The use of antioxidants with first‑line chemotherapy in two cases of ovarian cancer. J Am Coll Nutr. 2003 Apr;22(2):118-23. doi: 10.1080/07315724.2003.10719284. PMID: 12672707. 39. González J, Berdiel MJ, Miranda‑Massari MR, et al. High dose intravenous vitamin C and metastatic pancreatic can-
RkJQdWJsaXNoZXIy NDA4Mjc=